SNQ Quality Mark

SNQ is built on evidence-based standards, setting trusted quality and safety benchmarks for healthcare, biomedical, health, and animal care services and products.

  • 9F, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City, Taiwan
  • +886 2 2655 7888
  • snq@snq.com.tw

About the National Quality Mark

  • Vision & Mission
  • Review Committee
  • Certification Schedule

Certification Methods

  • Medical Service
  • Biomedical Product
  • Health Product
  • Animal Care & Products

SNQ Certified

  • Certified Services & Products
  • Certified Organizations
  • Quality Award Winners

International Certification

  • ICHOM PROMs
  • NSF Certification

Quality Focus

  • Apply for Certification →
Organized by|Research Center for Biotechnology and Medicine PolicyOperated by|Kuanglu International Quality Standards Co., Ltd.© 2026 Kuanglu International Quality Standards Co., Ltd. All rights reserved.Privacy Policy
SNQ Quality Mark
繁中
/
EN

Target Population

  • For elderly, comorbid, surgical high-risk patients, or those with renal insufficiency/solitary kidney.

  • For T1 RCC, AML, oncocytoma, TSC tumors, and small localized renal masses.

 


Description

Our team features "Cryoablation Therapy of Renal Tumor" as a core specialized medical service. The primary service targets are patients with early-stage renal tumors, including renal cell carcinoma, renal angiomyolipoma, and oncocytoma, with a particular focus on high-risk groups such as the elderly, those with multiple comorbidities, a single kidney, renal insufficiency, or those unfit for traditional surgery. The treatment utilizes image-guided minimally invasive cryoablation technology, combined with intraoperative CT, ultrasound 3D localization and precise anesthesia control to ensure the ice ball completely covers the tumor while maximizing the preservation of normal kidney tissue. Compared to traditional surgery, cryotherapy offers advantages such as lower complication rates, reduced risk of bleeding, shorter hospital stays, and better preservation of renal function, which helps enhance patient safety and quality of life. Through interdisciplinary collaboration among a multi-professional team, our hospital has established standardized protocols and a comprehensive follow-up mechanism to provide a safe, precise, and personalized treatment model for renal tumors.

 


Key Highlights

  • Intraoperative 3D CT-guided cryoablation for precise control of the treatment area.

  • Minimally invasive treatment to preserve renal function and reduce complications and hospital stays.

  • Interdisciplinary integrated team and standardized protocols to enhance patient safety and clinical efficacy.

 

Service Data

  • Near total 60 cases received this procedure.

  • Patient Distribution, 30-90 years-old ,Elderly patients over the age of 70 account for 28.3% of those receiving cryotherapy.


Featured Outcomes

  • Technical successful rate: 100%

  • Postoperative Care: The average hospital stay for cryotherapy patients is 3.02 days.

  • Probe Accuracy: The accuracy rate of intraoperative probe placement is greater than 95%.

  • Total Complication Rate: The postoperative total complication rate is only approximately 4%.


Safety Outcomes

  • Imaging Interpretation Consistency: Preoperative imaging interpretation consistency is greater than 90%.

  • Major Complication Rate: The incidence of post operation major complications is 0%.

  • Post operation infection rate: The incidence of post operation infection rate is 0%.


Satisfaction

  • Environmental Control Satisfaction: The average patient satisfaction for environmental control is 4.8 points (out of 5).

  • Respect and Care Satisfaction: The average satisfaction for respect and care towards patients reaches 4.8 points (out of 5).

  • Recommendation Willingness Index: More than 90% of patients stated they would recommend this treatment.


International Achievements

  • Inclusion in AUA Renal Tumor Treatment Guidelines

  • Cryotherapy listed as a first-line international option

  • Presentation of results at the ISQua 2023 International Conference


Benefits and Impacts

  • Enhancing Medical Quality: Utilizing CT-guided 3D positioning to precise cryoablation of renal tumor,small wound, lower infection rate, fast recover.

  • Establishing Treatment Standards: Developing standardized patient screening checklists and intraoperative dual-cycle cryoablation protocols to ensure treatment precision.

  • Significant Patient Benefits: Achieving an average hospital stay of only 3.02 days without blood flow occlusion, maximizing renal function preservation and improving quality of life.

  1. Home
  2. SNQ Certified
  3. Certified Services & Products
  4. Hospital
Specialized Medical Services

Renal Tumor Cryoablation Treatment

Our team offers precise, image-guided Cryoablation for renal tumors. It destroys tumors while sparing healthy tissue, ensuring low risk and quick recovery. Perfect for high-risk patients.
Organization
E-DA Health-Group E-DA Cancer Hospital
Specialties/Units
Department of Imaging Medicine、Department of Urology
Certification Year
2025
Renal Tumor Cryoablation Treatment
Renal Tumor Cryoablation Treatment
Renal Tumor Cryoablation Treatment